Zimbabwe has turned down a substantial US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to the United States' demand for confidential biological samples.
This move was revealed after a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "skewed".
A government spokesman has since explained that the US was seeking genetic material for scientific study and commercial gain but was unwilling to share the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued dialogue to reach a agreement agreeable to all parties so the country's vital HIV programme can continue.
Wider Background
This development follows a similar situation in Kenya, where a high court blocked a similar deal with the US following concerns were raised about the safety of citizens' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, 16 nations in Africa have so far signed these new health pacts, constituting more than $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," he stated.
"In essence, our nation would supply the raw materials for medical research without any certainty that the resulting innovations would be available to our people should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining structures previously set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This framework is designed to guarantee that when a country provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage ongoing dialogue with our American counterparts on how subsequent collaboration could be arranged in a way that respects the independence and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but suggested that talks must proceed given that much of the country's Aids initiatives depended on foreign aid.
"Where specific concerns arise, including those involving information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group commented.
The situation emphasises the complex tensions between accepting crucial international aid and protecting a country's data in an ever more data-driven world.